The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-14-2685
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Clear Cell Papillary Renal Cell Carcinoma in a Patient With Urothelial Papillary Carcinoma of Renal Pyelon – Report of a Case

Lijecnicki Vjesnik
Medicine
2018English

Papillary Renal Cell Carcinoma

2020English

Clear Cell Papillary Renal Cell Carcinoma

Archives of Pathology and Laboratory Medicine
MedicineForensic MedicinePathologyMedical Laboratory Technology
2019English

P3.13-29 Patient-Derived Xenograft Models(PDX) of Lung Squamous Cell Carcinoma(SCC) for Preclinical Studies

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Mp71-20 Patient-Derived Avatar Mouse Models Predicts Prognosis in Advanced Renal Cell Carcinoma.

Journal of Urology
Urology
2016English

Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models

Cells
2019English

Cryptotanshinone Suppresses Cell Proliferation and Induces Apoptosis in Renal Cell Carcinoma as an STAT3 Inhibitor

Cancer Cell & Microenvironment
2018English

Response to Crizotinib in a Patient With MET-mutant Papillary Renal Cell Cancer After Progression on Tivantinib

European Urology
Urology
2015English

Increased Intratumoral Fluorothymidine Uptake Levels Following Multikinase Inhibitor Sorafenib Treatment in a Human Renal Cell Carcinoma Xenograft Model

Oncology Letters
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy